EMERGENCY:Acute severe visual loss developing over hours to days with eye pain requires urgent same-day assessment at KIMS. Optic neuritis from NMOSD can cause severe, irreversible visual loss without prompt IV methylprednisolone. —call040-46324365immediately — 24 hours, 7 days— 24/7
Optic Neuritis in Hyderabad: Sudden Visual Loss and Eye Pain in a Young Adult — Is It Multiple Sclerosis or NMOSD, and What Must Be Done in the Next 24 Hours
Expert same-day MRI brain and orbits with gadolinium, AQP4-IgG (NMO-IgG) and MOG-IgG antibody testing, visual evoked potentials, CSF oligoclonal bands, IV methylprednisolone within hours of confirmation, plasma exchange for steroid-refractory NMOSD, and long-term immunosuppression (azathioprine, mycophenolate, rituximab, and newer biologics) at KIMS Neuroscience, Secunderabad, Hyderabad.
Optic neuritis is inflammation of the optic nerve (CN II), producing acute or subacute unilateral visual loss, usually with pain behind the eye worsened by eye movement. The most important clinical distinction: MS-related optic neuritis (most common) vs NMOSD optic neuritis (more severe, bilateral, can be permanently blinding without urgent IV methylprednisolone and maintenance immunosuppression). NMOSD is more prevalent in Asian women including Indian women than in Caucasian populations. AQP4-IgG and MOG-IgG antibody testing is mandatory at KIMS for all optic neuritis patients. Colour desaturation (red looks orange) is a sensitive early sign. Eye pain worsened by eye movement is present in 90% of optic neuritis patients and is pathognomonic. The Pulfrich phenomenon (asymmetric conduction velocity producing curved trajectory of moving objects) is a characteristic symptom.
- The diagnostic triad
- Subacute unilateral visual loss + pain behind the eye worsened by eye movement + relative afferent pupillary defect (RAPD). If all three are present in a young adult: optic neuritis until proven otherwise. Same-day MRI.
- Colour before acuity
- Colour desaturation (red looks orange or washed out) often precedes significant visual acuity loss. Sensitive early sign. Ishihara plates reveal colour vision deficit before Snellen acuity drops significantly.
- RAPD: the objective sign
- Swinging flashlight test: affected pupil dilates (paradoxically) when light moves to it from the normal eye. Cannot be faked. Persists even after visual acuity fully recovers — objective evidence of prior optic neuritis episode.
- MS vs NMOSD: the critical distinction
- MS: incomplete recovery rare · NMOSD: severe visual loss (counting fingers or worse), bilateral, permanent if untreated. AQP4-IgG positive = NMOSD in 70–80%. MOG-IgG = MOGAD in 20–30%.
- NMOSD in Indian women
- AQP4-IgG positive NMOSD is more prevalent in Asian women (including Indian women) than in Caucasian populations. Any bilateral or very severe optic neuritis in an Indian woman: AQP4-IgG and MOG-IgG testing is mandatory at KIMS.
- Treatment: MS vs NMOSD
- MS-related: IV methylprednisolone 1g x 3 days (accelerates recovery, does not improve final outcome) · NMOSD: IV methylprednisolone + plasma exchange if steroid-refractory + long-term azathioprine/MMF/rituximab. Untreated NMOSD: catastrophic.
- Emergency + contact
- 040-46324365 for acute visual loss · 040-44885000 for MRI orbits + brain + AQP4/MOG testing + VEP · NMOSD diagnosed = DO NOT stop treatment without specialist review.
| Fact | Details |
|---|---|
| Clinical features | Unilateral visual loss (hours–days) · Eye pain on movement (90%) · Colour desaturation (red–orange shift) · RAPD on swinging flashlight · Central scotoma |
| Pulfrich phenomenon | Asymmetric conduction velocity in the two optic nerves · Moving objects appear to take a curved trajectory · Characteristic but rarely documented by non-specialists |
| AQP4-IgG (NMOSD) | Positive in 70–80% of NMOSD · Mandates: aggressive IV methylprednisolone · Plasma exchange if steroid-refractory · Long-term azathioprine/MMF/rituximab · No treatment = repeated attacks, permanent blindness |
| MOG-IgG (MOGAD) | Positive in 20–30% of seronegative NMOSD · Distinct prognosis · Often responds well to steroids · Specific maintenance therapy differs from AQP4-NMOSD |
| MS risk at first optic neuritis | MRI brain lesions at onset: 72% MS risk at 10 years · Normal MRI: 25% MS risk · CSF oligoclonal bands support MS diagnosis · McDonald criteria may be met at first episode |
| India-specific | NMOSD more prevalent in Asian Indian women than Caucasians · AQP4/MOG testing at KIMS for all bilateral or severe optic neuritis · Same-day MRI orbits + brain |
| Newer NMOSD biologics | Inebilizumab · Satralizumab · Eculizumab · FDA approved for AQP4-positive NMOSD · Limited India access · KIMS coordinates access through manufacturer programmes |
About This Condition
Optic Neuritis at a Glance
The essential facts that shape how optic neuritis is recognised, classified, and treated at KIMS — from the clinical picture of acute unilateral visual loss with eye pain on movement, to the MS-vs-NMOSD distinction that determines treatment urgency, the antibody-driven NMOSD mechanism that mandates long-term immunosuppression, and the characteristic colour desaturation and Pulfrich phenomenon as sensitive early signs.
What it is
Optic neuritis is inflammation of the optic nerve (CN II), producing acute or subacute unilateral visual loss, usually with pain behind the eye worsened by eye movement. It is the most common presentation of demyelinating disease affecting the optic nerve. The vision typically worsens over 7–14 days. However, in neuromyelitis optica spectrum disorder (NMOSD), the visual loss can be severe and permanent without urgent treatment.
MS-associated optic neuritis (the most common form)
Optic neuritis is the presenting feature of multiple sclerosis (MS) in approximately 20–25% of MS patients and occurs at some point in the disease course in 50% of MS patients. The Optic Neuritis Treatment Trial (ONTT) established: IV methylprednisolone accelerates visual recovery but does not improve the final visual acuity; a first episode of optic neuritis with MRI brain lesions carries a 72% risk of MS diagnosis within 10 years; without MRI brain lesions, the 10-year MS risk is 25%. At KIMS, MRI brain at the time of first optic neuritis is essential for MS risk stratification.
NMOSD optic neuritis — the severe form that must not be missed
Neuromyelitis optica spectrum disorder (NMOSD) is caused by antibodies against aquaporin-4 (AQP4-IgG/NMO-IgG, in approximately 70–80%) or against myelin oligodendrocyte glycoprotein (MOG-IgG, in approximately 20–30%). NMOSD optic neuritis is typically more severe, more bilateral, and less completely reversible than MS-related optic neuritis. The vision can fall to counting fingers or worse. IV methylprednisolone is the acute treatment, and plasma exchange (plasmapheresis) is used for steroid-refractory cases. Long-term immunosuppression (azathioprine, mycophenolate, or anti-CD20 biologics) is mandatory to prevent relapse.
Colour vision and the Pulfrich phenomenon
Optic neuritis characteristically affects colour vision before or disproportionately to visual acuity: the affected eye perceives colours as less saturated, less vivid — red objects look orange or washed out. This colour desaturation is an important and sensitive early sign. The Pulfrich phenomenon — a specific distortion of moving objects' perceived trajectory caused by the asymmetric conduction velocity in the two optic nerves — is a characteristic and often described symptom of unilateral optic neuritis.
Appointment
040-44885000
The Eye That Could Not See Red
A 28-year-old woman in Hyderabad attends KIMS with a 5-day history of progressive visual blurring in her right eye, with a dull aching pain behind the right eye that worsens when she moves her eyes. She first noticed that red objects were appearing washed-out — a red saree she was wearing looked orange through the right eye. Her vision has progressively blurred and is now significantly reduced. She has no prior neurological history.
At KIMS, visual acuity is assessed: right eye 6/60 (severely reduced from her normal 6/6); left eye 6/6. Colour vision (Ishihara plates): right eye: 0/15 correct; left eye: 15/15. Pupil examination: the right pupil dilates when the light is swung to it from the left (relative afferent pupillary defect, RAPD — the right optic nerve transmits less light signal than the left, so swinging the light to the right produces paradoxical pupil dilation). Fundoscopy: mild optic disc swelling on the right (papillitis); the left disc is normal. These findings confirm right optic neuritis.
MRI brain with gadolinium and fat-suppressed orbital views: gadolinium enhancement of the right optic nerve (confirming active inflammation); 3 white matter lesions in the brain (periventricular and juxtacortical, characteristic of MS). Blood tests: AQP4-IgG (NMO-IgG): negative. MOG-IgG: negative. These antibody-negative findings, combined with the MRI brain lesions, are consistent with MS-related optic neuritis.
IV methylprednisolone 1g daily for 3 days is started at KIMS. At 6 weeks: visual acuity 6/9 on the right (significant recovery). Colour vision 12/15. The MRI brain lesions, combined with the clinical episode of optic neuritis, fulfil McDonald criteria for MS. A neurology follow-up for MS disease-modifying therapy is arranged at KIMS.
Book a Consultation
Speak directly with The KIMS Neuroscience team and the KIMS optic neuritis specialist team — neurology, neuro-ophthalmology, neuroradiology, immunology (AQP4 / MOG antibodies), neurophysiology (VEP) coordinated under one roof. Same-day MRI orbits and brain. No referral required. Monday to Saturday.
040-44885000Acute visual loss: 040-46324365Clinical Features
The clinical profile of optic neuritis spans the characteristic acute unilateral visual loss with central scotoma, the highly distinguishing eye pain worsened by eye movement, the objective relative afferent pupillary defect on swinging-flashlight testing, and the specific features that point to the more severe NMOSD form.
Acute unilateral visual loss — the presenting symptom
Visual loss in optic neuritis typically develops over hours to days, reaching its worst point in 1–2 weeks. The visual loss can range from mild (slight blur, noticed only when one eye is covered) to severe (perception of light only). The pattern of visual field loss in optic neuritis is typically central (a central scotoma — loss of vision in the central field while peripheral vision is preserved), reflecting the selective vulnerability of the papillomacular bundle within the optic nerve.
Eye pain worsened by eye movement — the distinguishing symptom
Pain behind the eye or around the orbit, specifically worsened by eye movement, is present in approximately 90% of optic neuritis patients and is one of its most diagnostically useful features. The pain reflects the inflammatory sheath around the optic nerve being mechanically stressed during eye movement. This pain-on-eye-movement combination distinguishes optic neuritis from ischaemic optic neuropathy (painless visual loss), macular degeneration (painless, central visual loss in elderly), and retinal detachment (painless, peripheral visual loss).
Relative afferent pupillary defect (RAPD) — the objective sign
The swinging flashlight test detects RAPD: a light swung from the normal eye to the affected eye causes the affected pupil to dilate (paradoxically) rather than constrict, because the damaged optic nerve transmits less afferent light signal from the affected eye. RAPD is an objective sign of unilateral optic nerve disease that cannot be faked and is not affected by pupil-dilating drops. Even when vision has fully recovered after optic neuritis, a subtle RAPD often persists, providing objective evidence of a prior episode on examination.
NMOSD optic neuritis — features that suggest the more severe form
Features that suggest NMOSD rather than MS-related optic neuritis: bilateral visual loss or sequential involvement of both eyes in rapid succession; very severe visual loss (counting fingers or worse); slow and incomplete visual recovery; absence of MS-typical brain MRI lesions; and presence of AQP4-IgG or MOG-IgG antibodies. NMOSD is more common in Asian women (including Indian women) than in Caucasian women, making the Indian prevalence of NMOSD-related optic neuritis higher than in Western practice. Any patient with bilateral or very severe optic neuritis must be tested for AQP4-IgG and MOG-IgG at KIMS.
Diagnosis at KIMS
Diagnosis at KIMS — MRI Orbits & Brain, AQP4 / MOG Antibodies, VEP & CSF
Optic neuritis diagnosis at KIMS combines MRI brain and orbits with gadolinium (essential for both confirming active optic nerve inflammation and MS risk stratification), AQP4-IgG and MOG-IgG antibody testing, visual evoked potentials (VEP) to document subclinical demyelination, and CSF oligoclonal-band analysis when MS is suspected.
MRI brain and orbits with gadolinium — essential
Orbital MRI with fat suppression and gadolinium enhancement identifies active optic neuritis (enhancement of the affected optic nerve) and quantifies optic nerve oedema. MRI brain: critically assesses for pre-existing white matter lesions that increase the risk of subsequent MS diagnosis (MAGNIMS/McDonald criteria for MS). At KIMS, the MRI protocol for optic neuritis always includes both orbital and brain sequences in a single study.
AQP4-IgG (NMO-IgG) and MOG-IgG antibody testing
Serum AQP4-IgG: positive in approximately 70–80% of NMOSD patients. A positive result in an optic neuritis patient immediately mandates: aggressive acute treatment (IV methylprednisolone; plasma exchange if steroid-refractory); and long-term maintenance immunosuppression (azathioprine, mycophenolate mofetil, or anti-CD20 biologics) to prevent relapse. MOG-IgG: positive in MOG antibody disease (MOGAD), which has a distinct prognosis and treatment (typically responds well to steroids but requires specific maintenance therapy). Both antibody tests are sent from KIMS to reference laboratories.
Visual evoked potentials (VEP) — the electrophysiological marker
The VEP measures the brain's electrical response to visual stimulation. Optic neuritis — and previous subclinical optic nerve demyelination — produces a prolonged P100 latency (the time from visual stimulus to the main cortical response is delayed). A delayed P100 latency is objective evidence of prior optic nerve demyelination, even when visual acuity has fully recovered. VEP at KIMS is used to document prior optic nerve involvement and to detect subclinical demyelination in the asymptomatic fellow eye.
CSF analysis — for oligoclonal bands and MS diagnosis
Lumbar puncture at KIMS when MS is suspected after a first episode of optic neuritis: oligoclonal IgG bands in the CSF (present in >90% of MS patients but absent in healthy controls and in most NMOSD patients) support the MS diagnosis and are part of the McDonald criteria for MS diagnosis at first demyelinating event. CSF also assesses for other inflammatory causes (sarcoid, infectious).
Treatment
Treatment at KIMS — IV Methylprednisolone, Plasma Exchange & Long-Term Immunosuppression
Optic neuritis treatment at KIMS is built around three integrated pillars — same-day IV methylprednisolone as acute therapy, plasma exchange for steroid-refractory cases (particularly NMOSD), and mandatory long-term immunosuppression with azathioprine, mycophenolate, rituximab, or newer biologics for NMOSD and MOGAD, with MS disease-modifying therapy referral for MS-related cases.
IV methylprednisolone, plasma exchange & long-term immunosuppression
Acute Treatment — IV Methylprednisolone: IV methylprednisolone 1 gram daily for 3 days (sometimes followed by oral prednisolone taper): the established acute treatment for optic neuritis. Accelerates visual recovery speed (patients see better 2–3 weeks earlier on methylprednisolone than without treatment) but does not improve the final visual outcome at 6 months. Reduces the short-term risk of MS relapse. In NMOSD optic neuritis — where the visual loss is more severe and recovery is less complete — early high-dose methylprednisolone is critical for preserving vision.
Plasma Exchange (Plasmapheresis) — for Steroid-Refractory Optic Neuritis: In patients with optic neuritis who show inadequate response to IV methylprednisolone (particularly NMOSD patients), plasma exchange (typically 5–7 sessions over 10–14 days) removes the pathogenic antibodies (AQP4-IgG, MOG-IgG) from the circulation and provides further visual recovery.
Long-Term Immunosuppression — for NMOSD and MOGAD: NMOSD relapses cause cumulative and severe visual and neurological disability. Long-term maintenance immunosuppression is essential. Azathioprine (2–3 mg/kg/day): widely used in India; effective; requires 3–6 months to reach full efficacy. Mycophenolate mofetil (1–2g/day): alternative to azathioprine; similar efficacy. Rituximab (IV anti-CD20): more effective than azathioprine/MMF for relapse prevention in AQP4-positive NMOSD; increasing use in India. Inebilizumab, satralizumab, eculizumab: newer targeted biologics approved for AQP4-positive NMOSD; limited access in India currently; KIMS coordinates access through manufacturer programmes. MS-related optic neuritis management overlaps with the MS disease-modifying therapy programme at KIMS.
Related Conditions
Optic neuritis belongs to the family of cranial nerve disorders evaluated and managed at KIMS Neuroscience:
FAQs
Frequently Asked Questions
Blurring vision in one eye. Pain when moving the eye. Red that looks orange. Optic neuritis is a neurological emergency in some forms and a harbinger of MS in others.
At KIMS Neuroscience, Secunderabad, Hyderabad, optic neuritis is assessed the same day with MRI orbits and brain, AQP4-IgG and MOG-IgG antibody testing, and VEP. IV methylprednisolone is started within hours. Emergency (acute visual loss): 040-46324365. Appointments: 040-44885000.
International enquiries: info@kimsneurosciences.com